Cutaneous side effects caused by treatment for inflammatory bowel disease

Dino K Tarabar; Lidija Kandolf Sekulović; Željka Tatomirović; Željko Mijušković; Zoran Milenković; Olivera Tarabar; Tanja Pecelj Broćić

doi:10.2298/9585

Dino K Tarabar Clinic for Gastroenterology and Hepatology Military Medical Academy, Belgrade, Serbia;Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia
Lidija Kandolf Sekulović Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia, Clinic for Dermatovenerology Military Medical Academy, Belgrade, Serbia
Željka Tatomirović Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia,Institute for Pathology and Forensic Medicine Military Medical Academy, Belgrade, Serbia
Željko Mijušković Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia, Clinic for Dermatovenerology Military Medical Academy, Belgrade, Serbia
Zoran Milenković Clinic for Gastroenterology and Hepatology,Military Medical Academy, Belgrade, Serbia
Olivera Tarabar Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia,Clinic for Hematology, Military Medical Academy, Belgrade, Serbia
Tanja Pecelj Broćić Clinic for Gastroenterology and Hepatology,Military Medical Academy, Belgrade, Serbia

DOI: https://doi.org/10.2298/9585

Keywords: inflammatory bowel diseases, therapeutics, drug hypersensitivity, skin, immunosuppressive agents, azathi-oprine, biological therapy, erythema nodosum, melanoma,

Abstract

References

Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H. Serious complications of sulfasalazine. Dis Colon Rectum 1986; 29(3): 201−2.

Ward SK, Roenigk HH, Gordon KB. Dermatologic manifestations of gastrointestinal disorders. Gastroenterol Clin North Am 1998; 27(3): 615−36, vi.

Sartor RB, Sandborn WJ. Kirsner's Inflammatory Bowel Diseases. 6th ed. New York, NY: Saunders; 2004.

Toruner M, Loftus EV, Harmsen SW, Zinsmeister AR, Orenstein R, Sandborn WJ, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134(4): 929−36.

Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflam-matory bowel disease. Clin Gastroenterol Hepatol 2006; 4(12): 1483−90.

Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, et al. Second European evidence-based con-sensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014; 8(6): 443−68.

El-Azhary RA, Brunner KL, Gibson LE. Sweet syndrome as a manifestation of azathioprine hypersensitivity. Mayo Clin Proc 2008; 83(9): 1026−30.

McNally A, Ibbetson J, Sidhu S. Azathioprine-induced Sweet's syndrome: A case series and review of the literature. Australas J Dermatol 2015; doi: 10.1111/ajd.12383. (In Press)

de Fonclare AL, Khosrotehrani K, Aractingi S, Duriez P, Cosnes J, Beaugerie L. Erythema nodosum-like eruption as a manifestation of azathioprine hypersensitivity in patients with inflammatory bowel disease. Arch Dermatol 2007; 143(6): 744−8.

O’ Donovan PO, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309(5742): 1871−4.

Patel AA, Swerlick RA, McCall CO. Azathioprine in dermatology: The past, the present, and the future. J Am Acad Dermatol 2006; 55(3): 369−89.

Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010; 8(3): 268−74.

Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011; 141(5): 1621−8. e1−5.

Guenova E, Lichte V, Hoetzenecker W, Woelbing F, Moehrle M, Roecken M, et al. Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine. Melanoma Res 2009; 19(4): 271−3.

Wolff T, Tai E, Miller T. Screening for skin cancer: An up-date of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 150(3): 194−8.

Harrison PV. Methotrexate-induced epidermal necrosis. Br J Dermatol 1987; 116(6): 867−9.

Maruani A, Wierzbicka E, Machet M, Abdallah-Lotf M, Muret A, Machet L. Reversal of multifocal cutaneous lymphoproliferative disease associated with Epstein-Barr virus after withdrawal of methotrexate therapy for rheumatoid arthritis. J Am Acad Dermatol 2007; 57(5 Suppl): S69−71.

Giard C, Avenel-Audran M, Croué A, Verret J, Martin L. Pri-mary cutaneous Epstein-Barr virus-associated B-cell lym-phoma arising at the site of subcutaneous injections of methotrexate. J Clin Oncol 2010; 28(34): e717−8.

Buchbinder R, Barber M, Heuzenroeder L, Wluka AE, Giles G, Hall S, et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 2008; 59(6): 794−9.

Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330(26): 1841−5.

Krupp P, Monka C. Side-effect profile of cyclosporin A in patients treated for psoriasis. Br J Dermatol 1990; 122(Suppl 36): 47−56.

Colombel J, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology 2007; 132(1): 52−65.

Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353(23): 2462−76.

Kerbleski JF, Gottlieb AB. Dermatological complications and safety of anti-TNF treatments. Gut 2009; 58(8): 1033−9.

Ramos-Casals M, Brito-Zerón P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008; 22(5): 847−61.

Gonnet-Gracia C, Barnetche T, Richez C, Blanco P, Dehais J, Schaeverbeke T.Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers. Clin Exp Rheumatol 2008; 26(3): 401-7.

Fiorino G, Danese S, Pariente B, Allez M. Paradoxical im-mune-mediated inflammation in inflammatory bowel dis-ease patients receiving anti-TNF-α agents. Autoimmun Rev 2014; 13(1): 15−9.

Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 2014; 63(4): 567−77.

Ettler J, Wetter DA, Pittelkow MR. Pityriasis amiantacea: A distinctive presentation of psoriasis associated with tumour necrosis factor-α inhibitor therapy. Clin Exp Dermatol 2012; 37(6): 639−41.

Seneschal J, Lepreux S, Milpied B, Schaeverbeke T, Taïeb A. Psoriasiform eruptions during anti TNF-alpha treatment: Psoriasis or not. Arch Dermatol 2007; 143(12): 1593−5.

Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerba-tion of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases. J Dermatolog Treat 2009; 20(2): 100−8.

Włodarczyk M, Sobolewska A, Wójcik B, Loga K, Fichna J, Wiśniewska-Jarosińska M. Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients. World J Gastroenterol 2014; 20(22): 7019−26.

El Shabrawi-Caelen L, La Placa M, Vincenzi C, Haidn T, Muellegger R, Tosti A. Adalimumab-induced psoriasis of the scalp with diffuse alopecia: A severe potentially irreversible cutaneous side effect of TNF-alpha blockers. Inflamm Bowel Dis 2010; 16(2): 182−3.

Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: Case series. J. Rheumatol 2003; 30(10): 2287−91.

Devos SA, Van Den Bossche N, De Vos M, Naeyaert JM. Ad-verse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology (Basel) 2003; 206(4): 388−90.

Mariette X, Tubach F, Bagheri H, Bardet M, Berthelot JM, Gaudin P, et al. Lymphoma in patients treated with anti-TNF: Results of the 3-year prospective French RATIO registry. Ann Rheum Dis 2010; 69(2): 400−8.

Singh S, Nagpal SJ, Murad MH, Yadav S, Kane SV, Pardi DS, et al. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014; 12(2): 210−8.

Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012; 143(2): 390−9.e1.

Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: A meta-analysis. Clin Gastroenterol Hepatol 2009; 7(8): 874−81.

Soh JS, Yun WJ, Kim K, Won CH, Park SH, Yang D, et al. Concomitant use of azathioprine/6-mercaptopurine de-creases the risk of anti-TNF-induced skin lesions. In-flamm Bowel Dis 2015; 21(4): 832−9.

Torres J, Buche S, Delaporte E, Colombel JF. Skin side ef-fects of inflammatory bowel disease therapy. Inflamm Bowel Dis 2013; 19(5): 1086−98.